# T Pensions Institute

## **DISCUSSION PAPER PI-0908**

## **On Stochastic Mortality Modeling**

**Richard Plat** 

March 2009

ISSN 1367-580X

The Pensions Institute Cass Business School City University 106 Bunhill Row London EC1Y 8TZ UNITED KINGDOM

http://www.pensions-institute.org/

#### **ON STOCHASTIC MORTALITY MODELING**

RICHARD PLAT<sup>a</sup> University of Amsterdam, Eureko / Achmea Holding and Netspar

This version: March 18, 2009<sup>1</sup>

#### Abstract

The last decennium a vast literature on stochastic mortality models has been developed. However, as far as we know, none of the existing models meet most of the criteria an insurer or pension fund would set for stochastic mortality models. All well known models have nice features but also disadvantages. In this paper a new stochastic mortality model is proposed that aims at combining the nice features from existing models, while eliminating the disadvantages. More specifically, the model fits historical data very well, is applicable to a full age range, captures the cohort effect, has a non-trivial (but not too complex) correlation structure and has no robustness problems, while the structure of the model remains relatively simple. Also, the paper described how to incorporate parameter uncertainty in the model. Furthermore, a risk neutral version of the model is given, that can be used for pricing.

Keywords: stochastic mortality models, longevity risk, pricing, Solvency 2, Monte Carlo simulation

#### 1. Introduction

In recent years there has been an increasing amount of attention of the insurance industry for the quantification of the risks that insurers are exposed to. Important drivers of this development are the increasing internal focus on risk measurement and risk management and the introduction of Solvency 2 (expected to be implemented around 2011).

Solvency 2 will lead to a change in the regulatory required solvency capital for insurers. At this moment this capital requirement is a fixed percentage of the mathematical reserve or the risk capital. Under Solvency 2 the so-called Solvency Capital Requirement (SCR) will be risk-based, and market values of assets and liabilities will be the basis for these calculations.

Also for pension funds, a new solvency framework will be developed, either as part of Solvency 2 or as a separate project (usually named IORP 2). It is expected that the general principles will be similar as Solvency 2, meaning market valuation of assets and liabilities and risk-based solvency requirements.

<sup>&</sup>lt;sup>1</sup> The author likes to thank Antoon Pelsser, Peter Boswijk, Marwa Khalaf-Allah, David Epstein and Andrew Cairns.

<sup>&</sup>lt;sup>a</sup> University of Amsterdam, Dept. of Quantitative Economics, Roetersstraat 11, 1018 WB Amsterdam, The Netherlands, e-mail: H.J.Plat@uva.nl

Important risks to be quantified are mortality and longevity risk. Not only is this an important risk for most (life) insurers and pension funds, the resulting solvency margin will also be part of the fair value reserve. Reason for this is that it is becoming best practice for the quantification of the Market Value Margin to apply a Cost of Capital rate to the solvency capital necessary to cover for unhedgeable risks, such as mortality and longevity risks.

There is a vast literature on stochastic modeling of mortality rates. Often used models are for example those of Lee and Carter (1992), Renshaw and Haberman (2006), Cairns et al (2006a), Currie et al (2004) and Currie (2006). For an extensive review we refer to section 2.

As far as we know, none of the existing models meet most of the criteria an insurer or pension fund would set for stochastic mortality models. All well known models have nice features but also disadvantages. In this paper a new mortality model is proposed that aims at combining the nice features from existing models, while eliminating the disadvantages of existing models. More specifically, the model fits historical data very well, is applicable to a full age range, captures the cohort effect, has a non-trivial (but not too complex) correlation structure, has no robustness problems and can take into account parameter risk, while the structure of the model remains relatively simple.

The remainder of the paper is organized as follows. First, in section 2 the existing literature review is extensively reviewed, focusing on stochastic mortality models and the criteria for them. In section 3 a new mortality model is proposed. Section 4 describes the fitting procedure of the model and gives results of the fitting process for mortality of different countries. Section 5 shows simulation results of mortality rates and the results of a robustness test. In section 6 a risk neutral version of the model is given, which can be used for pricing. Section 7 describes a possible method to account for parameter risk for the proposed mortality model. Conclusions are given in section 8.

#### 2. Literature review: criteria and models

Due to the increasing focus on risk management and measurement for insurers and pension funds, the literature on stochastic mortality models has developed rapidly during the last decennium. In this section an overview of current literature on stochastic mortality models and criteria for them is given.

#### 2.1 Criteria for stochastic mortality models

It is important to consider whether a specific stochastic mortality model is a good model or not. Therefore, Cairns et al (2008a) defined criteria against which a model can be assessed:

- Mortality rates should be positive.
- The model should be consistent with historical data.
- Long-term dynamics under the model should be biologically reasonable.

- Parameter estimates should be robust relative to the period of data and range of ages employed.
- Model forecasts should be robust relative to the period of data and range of ages employed.
- Forecast levels of uncertainty and central trajectories should be plausible and consistent with historical trends and variability in mortality data.
- The model should be straightforward to implement using analytical methods or fast numerical algorithms.
- The model should be relatively parsimonious.
- It should be possible to use the model to generate sample paths and calculate prediction intervals.
- The structure of the model should make it possible to incorporate parameter uncertainty in simulations.
- At least for some countries, the model should incorporate a stochastic cohort effect.
- The model should have a non-trivial correlation structure.

An important additional criterion is that the model is applicable for a full age range. Some models are designed for higher ages only (say 60 years or older). However, the portfolios of insurers and pension funds usually exist of policyholders from age 20 and older. One would want to model the mortality rates and their dependencies for the whole portfolio consistently, therefore the model should be applicable for the whole age ranges.

#### 2.2 Stochastic mortality models

Stochastic mortality models either model the central mortality rate or the initial mortality rate (see Coughlan et al (2007)). The central mortality rate  $m_{x,t}$  is defined as:

(2.1) 
$$m_{x,t} = \frac{D_{x,t}}{E_{x,t}} = \frac{\# deaths during calendar yeart aged x last birthday}{average population during calendar yeart aged x last birthday}$$

The initial mortality rate  $q_x$  is the probability that a person aged x dies within the next year. The different mortality measures are linked by the following approximation:

$$(2.2) \qquad q_x \approx 1 - e^{-m_x}$$

One of the most well known stochastic mortality models is the model of Lee and Carter (1992):

$$(2.3) \quad \ln(m_{x,t}) = a_x + b_x \kappa_t$$

where  $a_x$  and  $b_x$  are age effects and  $\kappa_t$  is a random period effect. Cairns et al (2007, 2008a and 2008b) noted several disadvantages of the Lee-Carter model:

- It is a 1-factor model, resulting in mortality improvements at all ages being perfectly correlated (trivial correlation structure).
- For countries where a cohort effect is observed in the past, the model gives a poor fit to historical data.

- The uncertainty in future death rates is proportional to the average improvement rate  $b_x$ . For high ages this can lead to this uncertainty being too low, since historical improvement rates have often been lower at high ages.
- The basic version of the model can result in a lack of smoothness in the estimated age effect  $b_x$ .

There is whole strand of literature on additions or modifications of the Lee-Carter model, for example Brouhns et al (2002), Lee and Miller (2001), Booth et al (2002), Girosi and King (2005), De Jong and Tickle (2006), Delwarde et al (2007) and Renshaw and Haberman (2003). Most of these models tackle one of the problems of the Lee-Carter model, but the other disadvantages still remain.

The first model that incorporated the cohort effect was proposed in Renshaw and Haberman (2006):

(2.4) 
$$\ln(m_{x,t}) = a_x + b_x^1 \kappa_t + b_x^2 \gamma_{t-x}$$

where  $\gamma_{t-x}$  is a random cohort effect that is a function of the year of birth (*t-x*). For countries where a cohort effect is observed in the past, this model provides a significant better fit to the historical data. However, CMI (2007) and Cairns et al (2007, 2008b) find that the Renshaw-Haberman suffers from a lack of robustness. Furthermore, although the model has an additional stochastic factor for the cohort effect, for most of the simulated mortality rates the correlation structure is still trivial. Especially when using a wide age range, the simulated cohort parameters are only relevant for the higher ages in the far end of the projection.

Currie (2006) introduced a simplification of the Renshaw-Haberman model that removes the robustness problem:

(2.5) 
$$\ln(m_{x,t}) = a_x + \kappa_t + \gamma_{t-x}$$

However, the fit quality is less compared with the Renshaw-Haberman model, and the problem with the trivial correlation structure still remains.

When fitting models (2.4) and (2.5) to an age range of say 20-85, the modeled cohort effect can result in odd looking humps in the projected mortality rates over time. This problem will be further highlighted in the next paragraph.

Furthermore, Cairns et al (2008b) observe that for United Kingdom and United States data, the fitted cohort effect appears to have a trend in the year of birth. This suggests that the cohort effect compensates the lack of a second age-period effect, as well as trying to capture the cohort effect in the data.

Cairns et al (2006a) introduced the following model:

(2.6) 
$$\operatorname{logit}(q_{x,t}) = \ln\left(\frac{q_{x,t}}{1-q_{x,t}}\right) = \kappa_t^1 + \kappa_t^2 \left(x - \overline{x}\right)$$

where  $\overline{x}$  is the mean age in the sample range and  $(\kappa_t^1, \kappa_t^2)$  is assumed to be a bivariate random walk with drift. Cairns et al (2007) also introduced some additions on model (2.6), amongst others capturing the cohort effect. The models have multiple factors that result in a (desired) non-trivial correlation structure, while the structure of the model is relatively simple. However, those models are all designed for higher ages only. When using these models for full age ranges, the fit quality will be relatively poor and the projections are likely to be biologically unreasonable.

#### 2.3 Problems with modeling cohort effect

Various explanations have been put forward for cohort effects that have been identified in the past. For example, for the United Kingdom Willets (2004) mentions historical patterns of smoking behavior and the impact of early life experience on health in later life. He states that there are a number of reasons to believe that this cohort effect will have an enduring impact on rates of mortality improvement in future decades.

The investigations on cohort effects often concentrate on birth years until about 1945. This is natural, since in most cases the cohort effect is an effect on health in later life, so one needs observations of mortality rates for middle age and higher ages to verify the existence of the cohort effect. When applying models (2.4) and (2.5) to a full age range, say 20-85, cohort parameters are also fitted for birth years 1945-1980. This means that for these birth years, (cohort) movements for young ages (which can be volatile) are projected into the future. This affects the mortality rates for higher ages in a similar degree, since the cohort effect is usually modeled in a multiplicative way. However, given the possible nature of the movements for these specific birth years (for example AIDS, drug and alcohol abuse and violence) it is unclear whether these effects do have a persistent effect on the future mortality rates for these cohorts. And if so, it is questionable whether a high relative cohort effect for young ages will have a similar relative effect on mortality of higher ages, given the nature of the cohort effect for young ages<sup>2</sup>.

Figure 1 shows a best estimate and percentiles of mortality rates for 75 years old males, using the Currie (2006) model applied to United States mortality for an age range of 20-84.

<sup>&</sup>lt;sup>2</sup> Note that the Renshaw-Haberman tries to capture this in the parameter  $b_x^2$ . However, this is based on the cohort effects for earlier birth years, which could have a significantly different nature.





The figure shows an odd-looking hump around 2020-2040 and flattening of projected mortality thereafter, corresponding with patterns in the fitted cohort parameters for birth years 1945-1980.

Given the considerations above and the odd-looking results when taking into account cohort effects of recent birth years, it might be wise to only include the cohort effect for early birth years (say until year 1945) in the fitting of the model. The cohort effect for later birth years (so > 1945) can be simulated from the fitted distributions. An additional advantage of this is that the simulation of the cohort effect becomes relevant for higher ages already in the beginning of the projection, leading to a non-trivial correlation structure.

#### 3. A new stochastic mortality model

The models mentioned in the previous section all have some nice features:

- the  $a_x$  term of the Lee-Carter model makes it suitable for full age ranges
- the Renshaw-Haberman model addresses the cohort effect and fits well to historical data
- the Currie model has a simpler structure then the Renshaw-Haberman model, making it more robust
- the models of Cairns et al (2006a, 2007) have multiple factors, resulting in a non-trivial correlation structure, while the structure of the model is relatively simple

In this section a new mortality model is proposed that combines those nice features, while eliminating the disadvantages mentioned in the previous section.

#### 3.1 The proposed model

As for most other stochastic mortality models, the quantity of interest is the central mortality rate  $m_{x,t}$ . The proposed model for  $m_{x,t}$  is:

(3.1) 
$$\ln(m_{x,t}) = a_x + \kappa_t^1 + \kappa_t^2 (\bar{x} - x) + \kappa_t^3 (\bar{x} - x)^+ + \gamma_{t-x}$$

where  $(\overline{x} - x)^+ = \max(\overline{x} - x, 0)$ . The model has 4 stochastic factors, but has a similar relatively simple structure as the Currie (2006) and the Cairns et al (2006a, 2007) models.

The  $a_x$  is similar as in the Lee-Carter model and makes sure that the basic shape of the mortality curve over ages is in line with historical observations. Next to the  $a_x$ , the model has 4 stochastic factors  $(\kappa_t^1, \kappa_t^2, \kappa_t^3, \gamma_{t-x})$ . The parameters of the model can be fitted using the methodology described in section 4, after which suitable ARIMA-processes are selected for the various factors.

The factor  $\kappa^1$  represents changes in the level of mortality for all ages. Following the reasoning in Cairns et al (2006b), the (long-term) stochastic process for this factor should not be mean reverting. Reason for this is that it is not expected that higher mortality improvements in some years will surely be compensated by lower mortality improvements in later years.

The factor  $\kappa^2$  allows changes in mortality to vary between ages, to reflect the historical observation that improvement rates can differ for different age classes.

Furthermore, historical data seems to indicate that the dynamics of mortality rates at lower ages (up to age 40 / 50) can be (significantly) different at some times. For example, think of developments like AIDS, drugs and alcohol abuse, and violence. The factor  $\kappa^3$  is added to capture these dynamics.

The factor  $\gamma_{t-x}$  is capturing the cohort effect, in the same way as the models of Currie (2006) and Cairns et al (2007). As mentioned in paragraph 2.2, the process for this factor should not have a trend. Therefore, a trendless mean reverting process will be assumed for  $\gamma_{t-x}$ .

Next to  $\gamma_{t-x}$ , the factors  $\kappa^2$  and  $\kappa^3$  allow the model to have a non-trivial correlation structure between ages. Fitting non-stationary ARIMA-process for factors  $\kappa^2$  and  $\kappa^3$  could result (in some scenarios) in projected scenarios where the shape of the mortality curve over ages is not biologically reasonable. Therefore, a stationary (mean reverting) process will be assumed for these factors.

In most cases mortality projections for a wide age range are needed. However, if one is only interested in higher ages (say age 60 and older), the factor  $\kappa^3$  is not needed and can be left out. This reduces the model to:

(3.2) 
$$\ln(m_{x,t}) = a_x + \kappa_t^1 + \kappa_t^2 (\overline{x} - x) + \gamma_{t-1}$$

This reduced model still has all the favorable characteristics of model (3.1), but is more suitable for high ages only.

#### 3.2 Identifiability constraints

Just like most stochastic mortality models, the proposed mortality model has an identifiability problem, meaning that different parameterizations could lead to identical values for  $\ln(m_{x,t})$ . Note that the following parameterization leads to similar values for  $\ln(m_{x,t})$ :

(3.3)  

$$\begin{aligned} \tilde{\gamma}_{t-x} &= \gamma_{t-x} + \psi_1 + \psi_2 \left( t - x \right) \\
\tilde{\kappa}_t^1 &= \kappa_t^1 + \psi_1 - d\overline{x}\psi_2 \\
\tilde{\kappa}_t^2 &= \kappa_t^2 + d\psi_2 \\
\tilde{a}_x &= a_x + (1 - d)\psi_2
\end{aligned}$$

where  $\psi_1$ ,  $\psi_2$  and *d* are constants.

This can be resolved by setting identifiability constraints. We use the approach of Cairns et al (2007, model M6) for this, leading to the following constraints:

(3.4) 
$$\sum_{c=c_0}^{c_1} \gamma_c = 0$$
$$\sum_{c=c_0}^{c_1} c \gamma_c = 0$$
$$\sum_t \kappa_t^3 = 0$$

where  $c_0$  and  $c_1$  are the earliest and latest year of birth to which a cohort effect is fitted, and c = t-x. The rationale behind the choice of first two constraints is that if the function  $\psi_1 + \psi_2(t-x)$  is fitted to  $\gamma_{t-x}$  the constraints ensure that  $\hat{\psi}_1 = \hat{\psi}_2 = 0$ . This results in a fitted process for  $\gamma_{t-x}$  that will fluctuate around 0 and there will be no constant trend up or down. This means that the constraints in (3.4) force the process of  $\gamma_{t-x}$  only to be used to capture the cohort effect and not to compensate lack of age-period effects. The third constraint is only used to normalize the estimates for  $\kappa^3$ .

Other approaches for setting the identifiability constraints are also possible, see for example Cairns et al (2007) and Renshaw and Haberman (2006).

#### 4. Fitting the model

An important aspect of stochastic mortality models is the quality of the fit of the model to historical mortality data. In this section the methodology for fitting the model is described, and a

comparison of fit quality with other models is made for mortality rates of the United States (US), England & Wales (E&W) and The Netherlands (NL).

#### 4.1 Fitting methodology

Brouhns et al (2002) described a fitting methodology for the Lee-Carter model based on a Poisson model. The main advantage of this is that it accounts for heteroskedasticity of the mortality data for different ages. This method has been used more commonly after that, also for other models, see for example Renshaw and Haberman (2003, 2006) and Cairns et al (2007).

This fitting methodology will be applied to the model proposed in section 3. Therefore, the number of deaths is modeled using the Poisson model, implying:

(4.1) 
$$D_{x,t} \sim \text{Poisson}(E_{x,t} m_{x,t})$$

where  $D_{x,t}$  is the number of deaths,  $E_{x,t}$  is the exposure (see (2.1)) and  $m_{x,t}$  is modeled as in (3.1). The parameter set  $\phi$  is fitted with maximum likelihood estimation, where the log-likelihood function of model (4.1) is given by:

(4.2) 
$$L(\phi; D, E) = \sum_{x,t} \left\{ D_{x,t} \ln \left[ E_{x,t} m_{x,t}(\phi) \right] - E_{x,t} m_{x,t}(\phi) - \ln \left( D_{x,t} \right) \right\}$$

Because of the specific nature of the problem, there are (as far as we know) no commercial statistical packages that implement this Poisson regression with constraints. Therefore we have used the R-code of the (free) software package "Lifemetrics" as a basis for fitting  $(4.2)^3$ . Another reason for using this is to make an honest comparison of the fit quality of the model proposed in this paper and existing models (also modeled in Lifemetrics), which is the topic of the next paragraph.

Besides estimates for  $a_x$ , the fitting procedure described above leads to time series of estimations of  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$ . The next step in fitting the model is selecting and fitting a suitable ARIMA-process to these time series (see paragraph 4.3).

#### 4.2 Comparison of fit quality with existing models

To evaluate whether the proposed model fits historical data well, we have fitted the model to three different data sets and compared the fitting results with those of models from the Lifemetrics toolkit. The three used data sets are:

- United States, Males, 1961-2005, ages 20-84
- England & Wales, Males, 1961-2005, ages 20-89
- The Netherlands, Males, 1951-2005, ages 20-90

The data consists of numbers of deaths  $D_{x,t}$  and the corresponding exposures  $E_{x,t}$  and is extracted from www.mortality.org<sup>4</sup>.

<sup>&</sup>lt;sup>3</sup> See <u>www.lifemetrics.com</u> and <u>http://www.r-project.org/</u>. Lifemetrics is an (open source) toolkit for measuring and managing longevity and mortality risk, designed by J.P. Morgan.

<sup>&</sup>lt;sup>4</sup> Note that a longer history is available. We used these historic periods (for the U.S. and E&W) to be able to roughly compare results with Cairns et al (2007) and Cairns et al (2008).

As in Cairns et al (2007), the models are compared using the Bayes Information Criterion (*BIC*). The measure *BIC* provides a trade-off between fit quality and parsimony of the model. The *BIC* is defined as:

(4.3) 
$$BIC = L(\hat{\phi}) - \frac{1}{2}K \ln N$$

where  $\hat{\phi}$  is the maximum likelihood estimate of the parameter vector, N is the number of observations and K is the number of parameters being estimated.

Table 1 gives a comparison of the fitting results (in terms of *BIC*) of the model proposed in section 3 and existing models (fitted with the Lifemetrics toolkit).

BIC mortality models *	U.S.	E&W	NL	
Plat	-24.506	-18.151	-18.425	
Renshaw-Haberman (2006)	-25.971	-18.062	-18.632	
Currie (2006)	-37.489	-19.805	-18.597	
Lee-Carter (1992)	-47.542	-22.949	-20.353	
Cairns et al (2007, model M7)	-56.571	-27.730	-21.055	
Cairns et al (2006)	-294.928	-66.744	-31.511	

Table 1: comparison BIC for proposed model and existing models

\* higher BIC is more favorable

The table shows that the proposed model comes out most favorable, closely followed by the Renshaw-Haberman model. The *BIC* for the other models is (sometimes significantly) less. The models of Cairns et al (2006a, 2007) do not perform very well for this age range, since they are designed for higher ages only.

In the fitting process of the models above the cohort effect was taken into account for all birth years of the dataset. However, given the reasons mentioned in paragraph 2.3, for the remaining of this paper we will exclude the cohort effect for birth years later than 1945 in the fitting of the model. In general this will reduce the quality of the fit somewhat, as is shown in table 2.

Table 2: results BIC when excluding cohorts > 19
--

BIC mortality models *	U.S.	E&W	NL
Plat	-24.506	-18.151	-18.425
Plat (exluding cohorts > 1945)	-32.392	-18.927	-18.378

\* higher BIC is more favorable

The fitting results of the model are still good when excluding the cohort effect for birth years > 1945, certainly considering the fact that the *BIC* of the other models which include a cohort

effect (Renshaw-Haberman (2006), Currie (2006) and Cairns et al (2007)) would also be less favorable when excluding these birth years<sup>5</sup>.

Note that the proposed model nests the model of Currie (2006). For nested models, the use of a likelihood ratio test is more appropriate than the use of the *BIC* measure. The likelihood ratio (*LR*) test can be used to test the null hypothesis that the nested model (in this case, the Currie (2006) model) is the correct model against the alternative that the more general model (the model proposed in this paper) is correct. The likelihood ratio test statistic is:

(4.4) 
$$\xi_{LR} = 2 \left[ L(\hat{\phi}) - L(\tilde{\phi}) \right]$$

where  $L(\hat{\phi})$  is the log-likelihood of the general model and  $L(\tilde{\phi})$  of the nested model.

Under the null hypothesis,  $\xi_{LR}$  has a Chi-squared distribution with *J* degrees of freedom, *J* being the additional parameters being estimated in the general model compared to the nested model. Therefore, the null hypothesis can be rejected if:

$$(4.5) \quad \xi_{LR} > \chi^2_{J,\alpha}$$

where  $\alpha$  is the significance level. Alternatively, the *p*-value can be determined for this test:

(4.6) 
$$p = 1 - \chi_J^{2^{-1}} \left( 2 \left[ L\left(\hat{\phi}\right) - L\left(\tilde{\phi}\right) \right] \right)$$

The *p*-value is the probability of obtaining the observed value, assuming that the null hypothesis is true. If the *p*-value is lower than  $\alpha$ , the null hypothesis is rejected. Table 3 shows the results of the likelihood ratio test for the three data sets.

	Likelihood Ratio	Degrees of	• •
	test statistic	freedom	p-value
U.S.	26.677	89	< 0,0001
E&W	4.023	89	< 0,0001
Holland	1.245	109	< 0,0001

Table 3: LR test, null hypothesis Currie (2006) model against proposed model

The table shows that for each data set the null hypothesis is rejected overwhelmingly. Therefore, the conclusion above (based on *BIC* results) that the model proposed in this paper is preferable to the nested Currie (2006) model is supported by the results from the likelihood ratio test.

<sup>&</sup>lt;sup>5</sup> An alternative way of presentation could be to exclude the birth years > 1945 for all models that include the cohort effect and compare the *BIC* on that basis. However, the other models are all fitted with the Lifemetrics tool that includes all birth years.

#### 4.3 Fitting the ARIMA processes – U.S. Males

In the remainder of this paper, we will focus on the population of U.S. males<sup>6</sup>. The next step in the process is selecting and fitting a suitable ARIMA-process to the time series of  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$ . The fitted parameters  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  for U.S. males are given in figure 2. The figure shows that the pattern of the important parameter  $\kappa^1$  is well-behaved. The patterns of the other parameters all reveal some autoregressive behavior.

Since the factor  $\kappa^1$  drives a significant part of the uncertainty in mortality rates, its relatively regular behavior (for this particular dataset) will also show in the projected uncertainty (in other words, the confidence intervals will be relatively narrow).



Figure 2: estimated values of  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$ 

Now for each of these time series all relevant ARIMA(p,d,q) processes for the range p, d, q = 0, 1, 2, 3 are fitted and the most favorable process in terms of *BIC* is selected. The selected ARIMA processes are:

-  $\kappa^1$ : ARIMA(0,1,0) -  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$ : ARIMA(1,0,0), no constant

It is commonly assumed that the process for  $\gamma_{t-x}$  is independent of the other processes, so the parameters of this process can be fitted independently using Ordinary Least Squares (OLS). The

 $<sup>^{6}</sup>$  To be able to compare simulation results with Cairns et al (2007), we can either use US males or E&W males. The choice for U.S. males is more or less arbitrary.

other processes can be fitted simultaneously using Seemingly Unrelated Regression (SUR, see Zellner (1963)).

Table 4 gives the fitted parameters and their standard errors (between brackets) and table 5 shows the fitted standard deviations (on the diagonal) and correlations.

Table 4: fitted parameters for the process  $y_{t+1} = \theta_1 + \theta_2 y_t$ 

Fit results	$\kappa^{1}$	$\kappa^2$	κ <sup>3</sup>	$\gamma_{t-x}$
$\theta_{I}$	-0,0131 (0,0022)			
$\theta_2$		0,9539 (0,0495)	0,8440 (0,0656)	0,9366 (0,0361)

 Table 5: fitted standard deviations (on the diagonal) and correlations

	$\kappa^{1}$	$\kappa^2$	$\kappa^{3}$	$\gamma_{t-x}$
$\kappa^{1}$	0,0150	0,2539	0,0274	0
$\kappa^2$	0,2539	0,0005	0,0144	0
κ <sup>3</sup>	0,0274	0,0144	0,0012	0
$\gamma_{t-x}$	0	0	0	0,0175

#### 5. Mortality projections – U.S. Males

Using the fitted ARIMA processes and the fitted values for  $a_x$  and  $\gamma_{t-x}$  (see Appendix A), future mortality rate scenarios for U.S. males can be constructed using Monte Carlo simulation. This section shows the simulation results. Furthermore, the robustness of the projections is tested, using a similar test as in Cairns et al (2008b).

#### 5.1 Simulation results – U.S. Males

Figure 3 shows simulation results for ages 25, 45, 65 and 84 for U.S. males. The best estimate projection is given and the 5% and 95% percentiles.

The results are biologically plausible. For higher ages, the widths of the confidence intervals are broadly similar as the models of which Cairns et al (2008b) concluded that they produced biologically plausible results. The results for younger ages (25 and 45) also seem plausible, where the observed historical variability is reflected in the confidence intervals.





#### 5.2 Robustness of simulation results

Some models suffer from a lack of robustness. For example, Cairns et al (2007, 2008b) find that the Renshaw-Haberman model is not robust for changes in range of years. They link this to the shape of the likelihood function. Robust models probably have a unique maximum that remains broadly unchanged when the range of years or ages is changed. Models that lack robustness possibly have more than one maximum, so when changing the range of years or ages the optimizer can jump from one local maximum to another, yielding different parameter estimates.

The model proposed in this paper is tested for robustness using the same test as in Cairns et al (2008b). This means that the simulation results above are compared with those of two sensitivities. These sensitivities are:

- 1) The model is fitted only to historical data from 1981-2005 (instead of 1961-2005)
- 2) The model (3.1) is fitted to historical data from 1961-2005, but the stochastic models for  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  are only fitted to a restricted set of parameter estimates (being only the final 24  $\kappa^{(i)}$ 's and the final 45  $\gamma_{t-x}$ 's)

Of course, if there is a change in trend or variability in the period 1981-2005 compared to 1961-2005, it is inevitable, for all models, that the simulation results will be somewhat different.

The results are given in appendix B and are not significantly different as the results shown in paragraph 5.1. The confidence intervals for age 25 are wider, due to the higher variability for younger ages in the past 25 years. Conclusion is that the proposed model is robust for the sensitivities given above.

Furthermore, a backtest is carried out, meaning that the model is fitted to historical data from 1961-1986 and the forecast results are compared with the actual observations for the period 1987-2005. Also for this backtest, the proposed model performs adequately (see the results in appendix B).

#### 6. Risk neutral specification of the model

The model proposed in section 3 is set up in the so-called real-world measure, suitable for assessing risks for example in the context of Solvency 2. For pricing instruments of which the payoff depends on future mortality rates, a risk adjusted pricing measure has to be defined. A common approach is to specify a risk neutral measure Q that is a suitable basis for pricing, see for example Milevsky and Promislow (2001), Dahl (2004), Schrager (2006), Cairns et al (2006a, 2006b) and Biffis et al (2006). The risk neutral specification proposed below is in line with the approach of Cairns et al (2006a).

Note that the market for longevity or mortality instruments is currently (very) far from complete. Consequence of this is that the risk neutral measure Q is not unique. Given the absence of any market price data, it seems wise to keep the specification of the risk neutral process relatively simple.

#### 6.1 Risk neutral dynamics

The stochastic process for the factors  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  in the real world measure *P* can generally be specified as:

(6.1) 
$$\mathbf{K}_{t} = \Theta \left( \mathbf{K}_{t-1}, \varepsilon_{t-1} \right) + \Sigma \mathbf{Z}_{t}^{P}$$

Where  $K_t$  is the vector with factors  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$ ,  $\Theta(K_{t-1}, \varepsilon_{t-1})$  is the drift of the process,  $\Sigma\Sigma'$  is the covariance matrix and  $Z^P$  is a 4 x 1 vector with standard normal random variables under measure *P*.

Now the proposed dynamics under the risk neutral measure Q are:

(6.2) 
$$\begin{aligned} \mathbf{K}_{t} &= \Theta \left( \mathbf{K}_{t-1}, \boldsymbol{\varepsilon}_{t-1} \right) + \Sigma \left[ \boldsymbol{Z}_{t}^{\mathcal{Q}} - \boldsymbol{\lambda} \right] \\ &= \Theta \left( \mathbf{K}_{t-1}, \boldsymbol{\varepsilon}_{t-1} \right) - \Sigma \, \boldsymbol{\lambda} + \Sigma \, \boldsymbol{Z}_{t}^{\mathcal{Q}} \end{aligned}$$

where the vector  $\lambda$  represents the "market price of risk" associated with the process K<sub>t</sub>. Like Cairns et al (2006a), we assume that the market price of risk is constant over time. When market prices for longevity or mortality derivatives are available, the vector  $\lambda$  should be calibrated in such a way that the theoretical prices under the measure Q are approximately equal to market prices.

#### 6.2 Calibration of the market price of risk

Currently, there is no developed market for longevity derivatives. However, Loeys et al (2007) have the opinion that q-forwards are most likely to become the basis a longevity market.

A q-forward is a simple capital market instrument with similar characteristics as an interest rate swap. The instrument exchanges a realized mortality rate in a future period for a pre-agreed fixed mortality rate. This is shown in figure 4. The pre-agreed fixed mortality rate is based on a projection of mortality rates, coming from the Lifemetrics toolkit.

#### Figure 4: working of a q-forward



For example, when the realized mortality rate is lower than expected, the pension / annuity insurer will receive a payment which (partly) compensates the increase of the expected value of the insurance liabilities (caused by the decreasing mortality rates).

The basis for the instrument is the (projected) mortality of a country population, not the mortality of a specific company or portfolio. This makes the product and the pricing very transparent compared to traditional reinsurance.

Although there have been some transactions involving q-forwards, currently no market quotes for q-forwards are publicly available. However, Loeys et al (2007) give an indication and examples on how such an instrument would be priced in practice. In absence of real market data, we calibrate the model to q-forward prices resulting from these examples.

Loeys et al (2007) give the following formula for setting the fixed q-forward rate:

(6.3) 
$$q_{forward} = (1 - horizon * Sharpe ratio * q_{vol}) * q_{expected}$$

where they have used 10 years for the horizon of the derivative, 25% for the Sharpe ratio and the volatility  $q_{vol}$  based on historical data. Table 6 shows the results for q-forwards with a horizon of 10 and starting ages of 35, 45, 55 and 65, where  $q_{expected}$  is based on model (3.1). Since in this paper the central mortality rate  $m_{x,t}$  is modeled, the results are also translated these terms, which makes the calibration easier.

Age start	Age end	q <sub>vol</sub>	<b>q</b> expected	$q_{forward}$	m expected	<b>m</b> forward	h
35	45	2,31%	0,306%	0,288%	0,307%	0,289%	0,060
45	55	1,53%	0,709%	0,682%	0,712%	0,685%	0,039
55	65	1,01%	1,618%	1,578%	1,632%	1,590%	0,026
65	75	1,47%	3,542%	3,412%	3,606%	3,471%	0,038

Table 6: indication q-forward rate for horizon 10 and translation to m-forward

Now interpreting  $m_{forward}$  as the expectation under the risk neutral measure and  $m_{expected}$  as the expectation under real world measure leads to:

(6.4) 
$$E^{Q}\left(m_{x_{end},t_{end}}\right) = g E^{P}\left(m_{x_{end},t_{end}}\right)$$

where  $x_{end}$  and  $t_{end}$  are age and year at the end of the contract and g can be extracted from the market (or in this case, from table 6). Taking logarithms leads to:

(6.5) 
$$\ln\left[E^{Q}\left(m_{x_{end},t_{end}}\right)\right] = \ln\left[g\right] + \ln\left[E^{P}\left(m_{x_{end},t_{end}}\right)\right]$$

Because the only difference between the processes under Q and P is in the drift term, we can assume that:

(6.6) 
$$\ln\left[E^{Q}\left(m_{x_{end},t_{end}}\right)\right] - \ln\left[E^{P}\left(m_{x_{end},t_{end}}\right)\right] = E^{Q}\left(\ln\left[m_{x_{end},t_{end}}\right]\right) - E^{P}\left(\ln\left[m_{x_{end},t_{end}}\right]\right) = \ln\left[g\right]$$

Now since this difference in the drift term is the matrix  $-\Sigma\lambda$ , for a horizon k the following holds:

(6.7) 
$$E^{Q}\left(\ln\left[m_{x_{end},t_{end}}\right]\right) - E^{P}\left(\ln\left[m_{x_{end},t_{end}}\right]\right) = -\sum_{t=1}^{k} W_{t} \Sigma \lambda$$

where  $W_t$  is the matrix of weights that are used to translate the values for  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  into values for  $\ln(m_{x,t})$ . This leads to:

$$(6.8) \qquad h = \sum_{t=1}^{k} W_t \Sigma \lambda$$

where  $h = -\ln[g]$ , of which the values are given in the table above. From (6.8) the market prices of risk can be solved:

(6.9) 
$$\hat{\lambda} = \left(\sum_{t=1}^{k} W_t \Sigma\right)^{-1} h$$

Now we use this formula to calibrate the market prices of risk to the q-forwards specified above. The weights matrices  $W_t$  vary slightly for each year *t* depending on the development of the age:

(6.10) 
$$W_{t} = \begin{pmatrix} 1 & (\overline{x} - 45) & (\overline{x} - 45)^{+} & 1 \\ 1 & (\overline{x} - 55) & (\overline{x} - 55)^{+} & 1 \\ 1 & (\overline{x} - 65) & (\overline{x} - 65)^{+} & c_{t} \\ 1 & (\overline{x} - 75) & (\overline{x} - 75)^{+} & 0 \end{pmatrix}$$

where  $c_t = 0$  for t < 5 and  $c_t = 1$  otherwise. Reason for this time dependence is that the simulated cohort effect gradually comes into the projections for age 65. The right bottom item of  $W_t$  is 0 because for age 75 the cohort effect does not play a role within the horizon of 10 year for this age.

Applying formula (6.9) using (6.10), the results in table 5 and the vector h from table 6 leads to the calibrated market prices of risk given in table 7.

Table 7: market prices of ris						
	λ					
$\kappa^{1}$	1,2430					
$\kappa^2$	0,9793					
κ <sup>3</sup>	-0,5756					
$\gamma_{t-x}$	-0,7338					

When the market develops and a number of q-forward prices are available, the market prices of risk can be calibrated by minimizing the squared errors between the theoretical prices and the market prices:

(6.11) 
$$\hat{\lambda} = M_{\lambda} in \sum_{i=1}^{p} \left( h_i - \sum_{t=1}^{k} W_t^i \Sigma \lambda \right)^2$$

where p is the number of q-forwards the model is calibrated to.

#### 7. Parameter Uncertainty

As mentioned in the criteria for stochastic mortality models in paragraph 2.1, the structure of the model should make it possible to incorporate parameter uncertainty in simulations. There are two possible approaches for including this parameter uncertainty:

- 1) Using a Bayesian framework, see Cairns (2000) and Cairns et al (2006a)
- 2) Simulate the parameter values using the estimates and the standard errors obtained in the estimation process

In a Bayesian framework a prior, possibly non-informative, distribution is assumed for the parameters. Combining this prior distribution with the sample data and the assumed density function of a particular stochastic process leads to a posterior distribution. This posterior distribution can be used to assess the parameter uncertainty.

Approach 2) uses the standard errors of the fitted parameters to incorporate the parameter uncertainty. When least squares or maximum likelihood estimation is used the estimators are either normally or asymptotically normally distributed.

While a Bayesian approach is more elegant than approach 2), it generally leads to significantly more complexity. Market Chain Monte Carlo (MCMC) methods or importance sampling might be necessary, because the posterior distribution often does not belong to a known class of probability density functions (see for example Kleibergen and Hoek (1996)). Since approach 1) and 2) should not lead to significantly different parameter uncertainty, it is questionable whether it is worth increasing the complexity of the model significantly for slightly more elegance. Therefore, our preference would be approach 2).

By using approach 2), parameter uncertainty can be incorporated in the model proposed in this paper. For the stochastic processes of  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  the estimates and standard errors given in table 4 can be used as the moments of the normal distributions of the parameters. For the parameter estimates of the  $\gamma_{t-x}$ 's (until birth year 1945) and the  $a_x$ 's the standard errors have to be calculated separately. Starting point for this (see for example Verbeek (2008)) is the vector of first derivatives of the log-likelihood function, the so-called score vector  $s(\phi)$ :

(7.1) 
$$s(\phi) = \frac{\partial L(\phi)}{\partial \phi} = \sum_{i=1}^{N} \frac{\partial L_i(\phi)}{\partial \phi} = \sum_{i=1}^{N} s_i(\phi)$$

where  $\phi$  is the parameter set,  $L_i(\phi)$  is de log-likelihood function for observation *i* and *N* is the number of observations. Now the covariance matrix  $V_{par}$  to be used can be estimated with:

(7.2) 
$$V_{par} = \left(\sum_{i=1}^{N} s_i \left(\hat{\phi}\right) s_i \left(\hat{\phi}\right)'\right)^{-1}$$

The standard errors for the  $\gamma_{t-x}$ 's (until birth year 1945) and the  $a_x$ 's are the square roots of the relevant diagonal elements.

#### 8. Conclusions

As far as we know, none of the existing stochastic mortality models meet most of the criteria an insurer or pension fund would set. In this paper a new stochastic mortality model is proposed that aims at combining the nice features from existing models, while eliminating the disadvantages. The paper shows that the fit of the model to historical data is better than the well-known mortality models. Also, the model has 4 stochastic factors, leading to a (desired) non-trivial (but not too complex) correlation structure between ages. Due to a (Lee-Carter type) variable that describes the shape of the model is applicable to a full age range. Furthermore, the model captures the cohort effect and has no robustness problems. The paper also describes how to incorporate parameter uncertainty into the model.

For pricing purposes, a risk neutral version of the model is given, that can be used for pricing. This model is calibrated to some indicative prices for longevity derivatives.

### Appendix A: U.S. Male - estimates for $a_x$ and $\gamma_{t-x}$

age	a <sub>x</sub>	age	a <sub>x</sub>		birth year	$\gamma_{t-x}$	birth year	γ <sub>t-x</sub>
20	-6,3983	53	-4,6403		1881	-0,1202	1914	0,0773
21	-6,3328	54	-4,5587		1882	-0,1103	1915	0,0708
22	-6,3382	55	-4,4660		1883	-0,1057	1916	0,0609
23	-6,3483	56	-4,3843		1884	-0,0940	1917	0,0544
24	-6,3826	57	-4,3008		1885	-0,0839	1918	0,0603
25	-6,3812	58	-4,1935		1886	-0,0743	1919	0,0340
26	-6,3777	59	-4,1249		1887	-0,0967	1920	0,0554
27	-6,3645	60	-4,0197		1888	-0,0553	1921	0,0366
28	-6,3301	61	-3,9471		1889	-0,0321	1922	0,0400
29	-6,3426	62	-3,8376		1890	-0,0370	1923	0,0313
30	-6,3080	63	-3,7746		1891	-0,0574	1924	0,0376
31	-6,2548	64	-3,7040		1892	-0,0361	1925	0,0402
32	-6,2078	65	-3,6100		1893	-0,0074	1926	0,0361
33	-6,1571	66	-3,5483		1894	-0,0067	1927	0,0297
34	-6,1303	67	-3,4648		1895	0,0075	1928	0,0203
35	-6,0643	68	-3,3801		1896	0,0329	1929	-0,0057
36	-6,0026	69	-3,3068		1897	0,0244	1930	-0,0050
37	-5,9383	70	-3,2088		1898	0,0321	1931	-0,0184
38	-5,8493	71	-3,1444		1899	0,0016	1932	-0,0152
39	-5,8183	72	-3,0406		1900	0,0576	1933	-0,0128
40	-5,7386	73	-2,9656		1901	0,0834	1934	-0,0360
41	-5,6532	74	-2,8864		1902	0,0396	1935	-0,0347
42	-5,5658	75	-2,7994		1903	0,0703	1936	-0,0477
43	-5,4921	76	-2,7193		1904	0,0711	1937	-0,0651
44	-5,4221	77	-2,6375		1905	0,0702	1938	-0,0717
45	-5,3288	78	-2,5568		1906	0,0690	1939	-0,0751
46	-5,2423	79	-2,4671		1907	0,0705	1940	-0,0709
47	-5,1539	80	-2,3649		1908	0,0809	1941	-0,0697
48	-5,0575	81	-2,2824		1909	0,0615	1942	-0,0914
49	-4,9965	82	-2,1863		1910	0,0749	1943	-0,0632
50	-4,8950	83	-2,0906		1911	0,0785	1944	-0,0831
51	-4,8109	84	-1,9992	_	1912	0,0655	1945	-0,0702
52	-4,7155				1913	0,0765		

#### Appendix B: simulation results robustness tests

In this appendix the simulation results are given for the sensitivities that have been specified to test the robustness of the model:

- 1) The model is fitted only to historical data from 1981-2005 (instead of 1961-2005)
- 2) The model (3.1) is fitted to historical data from 1961-2005, but the stochastic models for  $\kappa^1$ ,  $\kappa^2$ ,  $\kappa^3$  and  $\gamma_{t-x}$  are only fitted to a restricted set of parameter estimates (being only the final 24  $\kappa^{(i)}$ 's and the final 45  $\gamma_{t-x}$ 's)

Figure B.1: simulation results sensitivity 1









Figure B3: simulation results backtest



#### References

BIFFIS, E., M. DENUIT, AND P. DEVOLDER (2006): Stochastic mortality under measure changes, *Pensions Institute Discussion Paper PI-0512* 

BOOTH, H., J. MAINDONALD AND L. SMITH (2002): Applying Lee-Carter under conditions of variable mortality decline, *Population Studies* 56, 325-336

BROUHNS, N., M. DENUIT, AND J.K. VERMUNT (2002): A Poisson log-bilinear regression approach to the construction of projected life tables, *Insurance: Mathematics and Economics 31*, 373-393

CAIRNS, A.J.G. (2000): A discussion of parameter and model uncertainty in insurance, *Insurance: Mathematics and Economics* 27, 313-330

CAIRNS, A.J.G., D. BLAKE, AND K. DOWD (2006a): A two-factor model for stochastic mortality with parameter uncertainty: Theory and Calibration, *Journal of Risk and Insurance* 73, 687-718

CAIRNS, A.J.G., D. BLAKE, AND K. DOWD (2006b): Pricing death: Frameworks for the valuation and securitization of mortality risk, *ASTIN Bulletin 36*, 79-120

CAIRNS, A.J.G., ET AL (2007): A quantitative comparison of stochastic mortality models using data from England & Wales and the United States, *Working paper, Heriot-Watt University, and Pensions Institute Discussion Paper PI-0701* 

CAIRNS, A.J.G., D. BLAKE, AND K. DOWD (2008a): Modelling and Management of Mortality Risk: A Review, Working paper, Heriot-Watt University, and Pensions Institute Discussion Paper PI-0814

CAIRNS, A.J.G., ET AL (2008b): The plausibility of mortality density forecasts: an analysis of six stochastic mortality models, *Working paper, Heriot-Watt University, and Pensions Institute Discussion Paper PI-0801* 

CONTINUOUS MORTALITY INVESTIGATION (2007): Stochastic projection methodologies: Lee-Carter model features, example results and implications, *Working paper 25* 

COUGHLAN, G. ET AL (2007): Lifemetrics Technical Document, available at:

http://www.jpmorgan.com/pages/jpmorgan/investbk/solutions/lifemetrics

CURRIE, I.D. (2006): Smoothing and forecasting mortality rates with P-splines, *Talk given at the Institute of Actuaries, June 2006, available at: http://www.ma.hw.ac.uk/~iain/research/talks.html* DAHL, M. (2004): Stochastic mortality in life insurance: Market reserves and mortality-linked

insurance contracts, Insurance: Mathematics and Economics 35, 113-136

DELWARDE, A., M. DENUIT AND P. EILERS (2007): Smoothing the Lee-Carter and Poisson logbilinear models for mortality forecasting: A penalized log-likelihood approach, *Statistical Modelling* 7, 29-48

DE JONG, P., AND L. TICKLE (2006): Extending the Lee-Carter model of mortality projection, *Mathematical Population Studies 13*, 1-18

KLEIBERGEN, F., AND H. HOEK (1996): Bayesian Analysis of ARMA Models using Noninformative Priors, *Tinbergen Institute discussion paper* 

LEE, R.D., AND L.R. CARTER (1992): Modelling and forecasting U.S. mortality, *Journal of the American Statistical Association* 87, 659-675

LEE, R., AND T. MILLER (2001): Evaluating the performance of the Lee-Carter model for forecasting mortality, *Demography 38*, 537-549

LOEYS ET AL (2007): Longevity: a market in the making, *available at:* 

http://www.jpmorgan.com/pages/jpmorgan/investbk/solutions/lifemetrics

MILEVSKY, M.A., AND S.D. PROMISLOW (2001): Mortality derivatives and the option to annuities, *Insurance: Mathematics and Economics* 29, 299-318

RENSHAW, A.E., AND S. HABERMAN (2003): Lee-Carter mortality forecasting with age-specific enhancement, *Insurance: Mathematics and Economics* 33, 255-272

RENSHAW, A.E., AND S. HABERMAN (2006): A cohort-based extension to the Lee-Carter model for mortality reduction factors, *Insurance: Mathematics and Economics* 38, 556-570

SCHRAGER, D.F. (2006): Affine stochastic mortality, *Insurance: Mathematics and Economics 38*, 81-97

VERBEEK, M. (2008): Modern Econometrics, 3th edition, John Wiley & Sons, Ltd

WILLETS, R.C. (2004): The cohort effect: Insights and explanations, *British Actuarial Journal 10*, 833-877

ZELLNER, A. (1963): Estimators of Seemingly Unrelated Regressions: Some Exact Finite Sample Results, *Journal of the American Statistical Association* 58, 977-992